National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Trastuzumab emtansine (Kadcyla®) is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.

Rapid Review

Commenced Completed Outcome
25/09/2013 24/10/2013 Full Pharmacoeconomic Evaluation recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 05/02/2014  30/06/2014  Reimbursement not Recommended

The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.

Trastuzumab emtansine summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.